Grifols Sa Barc Ord New (GIFLF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and thank you for joining us today for Grifold's full quarter and full year 2025 earnings call. My name is Dani Segarra and I serve as a head of investor relations and sustainability. Today I'm joined by Grifold's chief executive officer, Nat Shabia, president of BioPharma, Roland Vandeler, and chief financial officer, Rahul Esrinivasan. As usual is our usual practice, today's call will last about an hour, including the Q&A session. Please note that this call is being recorded. You can find additional materials, including today's presentations, in the investor relations section of the Grifols website at grifols.com. A transcript and reply of the webcast will also be available on the investor relations website within 24 hours. Turning to slide two, I would like to remind everyone that forward-looking statements may be made during this call. This may include, among other things, comments regarding the company's future operating and financial performance, statements about our future expectations, clinical developments, regulatory timelines, and the potential success of our product candidates. These statements are based on current expectations and available information as of the date of this call and are subject to certain risks and uncertainties that may cause actual results to differ materially from those discussed today. Grieval financial statements are prepared in accordance with EU IFRS and other applicable reporting provisions including alternative performance measures or APMs as defined by the European Securities and Markets Authority. Default management uses APMs to evaluate financial performance as the basis for operational and strategic decision making. These APMs are prepared for all the time periods presented in this document. Now, moving to to...